Brought to you by 
Novartis Venture Funds leads Visiogen's $40mm Series E round
30 Apr 2009
Executive Summary
Novartis Venture Funds has led the $40mm Series E financing for Visiogen (presbyopia- and cataract-correcting devices) and contributed a new board member. Technology Partners, another first-time investor, also contributed significantly and was joined by existing backers Three Arch Partners, New Leaf Venture Partners, Prospect Venture Partners, CMEA Ventures, and Foundation Medical Partners. The company will use the money to fund global commercialization of its accommodating intra-ocular lens Synchrony, which was recently launched in Europe and could be approved in the US next year. Including this round, Visiogen has raised over $80mm since it was founded in 2001.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis Venture Funds leads Visiogen's $40mm Series E round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice